More than 20 years ago, the first patients were enrolled in the phase 1 trial of imatinib for treatment of chronic myeloid leukemia (CML).1 Inhibiting the kinase activity of the BCR-ABL1 fusion protein, the driving molecular abnormality of this disease, has rendered this once deadly leukemia a manageable condition. For patients with CML, a good disease outcome with nearly normal lifespan is expected, but treatment adverse effects remain a significant issue.2 While adverse effect profiles vary between drugs, many patients report decreased energy, diffuse pain, gastrointestinal upset, depressed mood, and additional adverse effects that are detrimental to their quality of life. Driven by a desire to decrease the burden of adverse effects, there has been extensive interest in whether some patients might safely discontinue treatment and experience long periods of treatment-free remission (TFR).
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Braun TP, Druker BJ. Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia: Updates From the LAST Study on Patient-Reported Outcomes and Biomarkers for Relapse. JAMA Oncol. 2021;7(1):50–51. doi:10.1001/jamaoncol.2020.5772
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: